Williams & Connolly
Firm overview:
Williams & Connolly remains a highly active and influential presence in bet-the-company patent litigation at both trial and appellate levels, advising major global brands in some of the most consequential intellectual property disputes of 2025. A peer believes the firm to be among the best of the US “on the most high-profile matters”.
The firm continues to be especially prominent in Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) patent litigation, representing brand-name pharmaceutical companies defending market exclusivity against generic and biosimilar challengers.
Williams & Connolly’s longstanding client roster has included industry leaders such as Pfizer, Genentech, Merck, Bayer, AstraZeneca and Eli Lilly, who have turned to the firm for strategy and courtroom advocacy in high-stakes patent cases.
Beyond pharmaceuticals, the firm continues to handle significant patent and IP disputes for major technology companies and has an extensive history of involvement in inter partes review proceedings before the Patent Trial and Appeal Board, acting as lead counsel for both patent owners and petitioners in dozens of PTAB matters.
Team overview:
Williams & Connolly’s patent litigation strength is built on a core group of trial lawyers with deep technical and strategic experience.
Litigator Luke McCloud is singled out by a peer as being a “top” attorney for patent matters. McCloud’s clients have included global pharmaceutical and medical device manufacturers, leading technology companies, financial institutions, law firms, and individuals. He is an experienced appellate advocate.
Thomas Selby, former co-chair of the firm’s Patent Litigation practice group, has led complex IP disputes spanning software, biotech, pharmaceutical and communications technologies. His experience includes serving as lead counsel for clients such as Pfizer, Medtronic and Dropbox, with an additional focus on professional liability defence.
David Krinsky remains a key partner within the firm’s patent and high-technology litigation practice. With particular expertise in Hatch-Waxman pharmaceutical patent disputes and a background in software engineering, Krinsky is recognised for his ability to navigate highly technical computer and technology-related matters.
Key matters:
- Bayer v Mylan Pharmaceuticals, Teva Pharmaceuticals, Invagen Pharmaceuticals
William & Connolly’s Dov Grossman argued for Bayer in its appeal of a PTAB decision that invalidated a US patent related to administering rivaroxaban and aspirin.
The US Court of Appeals for the Federal Circuit affirmed the PTAB’s decision holding certain claims unpatentable, vacated the judgment of unpatentability with respect to other claims, and remanded for further proceedings.
- Genetech v Biogen
Williams & Connolly secured a major trial success in Genentech’s breach-of-contract and unpaid royalties case against Biogen, where the court entered judgment in September 2025 awarding over $88 million in damages based on a jury-trial record, a notable result for a life sciences patent-related dispute.
Clients:
Bayer,Genentech, Regeron Pharmaceuticals
